TY - JOUR
T1 - Immune checkpoint blockade in infectious diseases
AU - Wykes, Michelle N.
AU - Lewin, Sharon R.
N1 - Funding Information:
The authors sincerely thank M. Flynn for the design and implementation of the figures. The authors acknowledge editorial assistance of S. Johnatty from SugarApple Communications in finalizing the manuscript. The authors thank N. Chomont, University of Montreal, for helpful comments and discussion. The authors acknowledge the support of The National Health and Medical Research Council (NHMRC) (Australia). S.R.L. is an NHMRC practitioner fellow and is supported by the National Institutes for Health Delaney AIDS Research Enterprise (DARE U19 AI126611 and AI096109) and the American Foundation for AIDS Research.
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
AB - The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
UR - http://www.scopus.com/inward/record.url?scp=85041313801&partnerID=8YFLogxK
U2 - 10.1038/nri.2017.112
DO - 10.1038/nri.2017.112
M3 - Review article
C2 - 28990586
AN - SCOPUS:85041313801
SN - 1474-1733
VL - 18
SP - 91
EP - 104
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 2
ER -